​

Neurogene (NGNE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

NGNE Stock Forecast

Neurogene (NGNE) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $45.00, with a high of $45.00 and a low of $45.00. This represents a 45.07% increase from the last price of $31.02.

$20 $27 $34 $41 $48 $55 High: $45 Avg: $45 Low: $45 Last Closed Price: $31.02

NGNE Stock Rating

Neurogene stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

NGNE Price Target Upside V Benchmarks

TypeNameUpside
StockNeurogene45.07%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts118
Avg Price Target$45.00$45.00$45.00
Last Closing Price$31.02$31.02$31.02
Upside/Downside45.07%45.07%45.07%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2515---6
Sep, 2516---7
Aug, 2516---7
Jul, 25161--8
Jun, 25241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 02, 2025H.C. Wainwright$45.00$20.61118.34%45.07%
Apr 14, 2025Keith TapperBMO Capital$16.00$10.8946.92%-48.42%
Mar 25, 2025Joel BeattyRobert W. Baird$38.00$14.20167.61%22.50%
Mar 25, 2025Mitchell KapoorH.C. Wainwright$50.00$14.20252.11%61.19%
Nov 20, 2024Paul MatteisStifel Nicolaus$46.00$15.33200.07%48.29%
Nov 19, 2024Keith TapperBMO Capital$45.00$35.5926.44%45.07%
Nov 12, 2024Keith TapperBMO Capital$60.00$64.48-6.95%93.42%
Nov 12, 2024Paul MatteisStifel Nicolaus$60.00$64.48-6.95%93.42%
Aug 12, 2024Mitchell KapoorH.C. Wainwright$49.00$35.5937.68%57.96%
Jun 26, 2024Keith TapperBMO Capital$65.00$32.01103.06%109.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 02, 2025H.C. WainwrightBuyBuyhold
Jun 17, 2025Craig-HallumBuyinitialise
Jun 12, 2025BMO CapitalOutperformOutperformhold
Apr 14, 2025BMO CapitalOutperformOutperformhold
Mar 25, 2025H.C. WainwrightBuyBuyhold
Nov 19, 2024BMO CapitalOutperformOutperformhold
Oct 16, 2024BMO CapitalOutperformOutperformhold
Aug 14, 2024BMO CapitalOutperformOutperformhold
Aug 12, 2024H.C. WainwrightBuyBuyhold
Jun 26, 2024BMO CapitalOutperforminitialise

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.83-----
Avg Forecast$-5.58$-4.26$-4.22$-5.01$-4.54$-4.61
High Forecast$-4.71$-3.68$-3.30$-4.42$-4.50$-4.61
Low Forecast$-6.44$-4.51$-4.64$-5.63$-4.58$-4.61
Surprise %-49.28%-----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$905.00K-$462.50K-$33.00M
High Forecast-$924.89K-$462.50K-$33.00M
Low Forecast-$895.05K-$462.50K-$33.00M
Surprise %------

Net Income Forecast

$-85M $-75M $-65M $-55M $-45M $-35M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.32M$-75.14M----
Avg Forecast$-71.51M$-52.50M$-50.92M$-64.41M$-58.25M$-59.18M
High Forecast$-60.42M$-47.19M$-42.30M$-56.67M$-57.72M$-59.18M
Low Forecast$-82.60M$-57.81M$-59.53M$-72.16M$-58.78M$-59.18M
Surprise %-49.22%43.13%----

NGNE Forecast FAQ

Is Neurogene stock a buy?

Neurogene stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Neurogene is a favorable investment for most analysts.

What is Neurogene's price target?

Neurogene's price target, set by 5 Wall Street analysts, averages $45 over the next 12 months. The price target range spans from $45 at the low end to $45 at the high end, suggesting a potential 45.07% change from the previous closing price of $31.02.

How does Neurogene stock forecast compare to its benchmarks?

Neurogene's stock forecast shows a 45.07% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Neurogene over the past three months?

  • October 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Neurogene’s EPS forecast?

Neurogene's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.22, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-5.01 in 2026, $-4.54 in 2027, and $-4.61 in 2028.

What is Neurogene’s revenue forecast?

Neurogene's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $462.5K, followed by $0 for 2027, and $33M for 2028.

What is Neurogene’s net income forecast?

Neurogene's net income forecast for the fiscal year ending in December 2025 stands at $-50.916M, representing a -32.24% decrease from the reported $-75.144M in 2024. Projections indicate $-64.414M in 2026, $-58.249M in 2027, and $-59.181M in 2028.